FCGR3A and atherosclerosis: Further exploration of the relationship between intermediate (CD14++CD16+) monocytes and atherosclerosis will significantly advance our understanding of pro-atherogenic conditions and aide in the design of novel cell-directed therapies for the treatment of atherosclerosis.